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Abstract
Diffusion weighted magnetic resonance imaging (DWI) 
is an imaging technique which provides tissue contrast 
by the measurement of diffusion properties of water 
molecules within tissues. Diffusion is expressed in an 
apparent diffusion coefficient (ADC), which reflects 
the diffusion properties unique to each type of tissue. 
DWI has been originally used in neuroradiology. More 
recently, DWI has increasingly been used in addition 
to conventional unenhanced and enhanced magnetic 
resonance imaging (MRI) in other parts of the body. 
The reason for this delay was a number of technical 
problems inherent to the technique, making DWI very 
sensitive to artifacts, which had to be overcome. With 
assessment of ADC values, DWI proved to be helpful 
in characterization of focal liver lesions. However, DWI 
should always be used in conjunction to conventional 
MRI since there is considerable overlap between ADC 
values of benign and malignant lesions. DWI is useful 
in the detection of hepatocellular carcinoma in the 
cirrhotic liver and detection of liver metastases in 
oncological patients. In addition, DWI is a promising 
tool in the prediction of tumor responsiveness to 
chemotherapy and the follow-up of oncological patients 
after treatment, as DWI may be capable of detecting 
recurrent disease earlier than conventional imaging. 
This review focuses on the most common applications 
of DWI in the liver.
© 2010 Baishideng. All rights reserved.
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Magnetic resonance imaging (MRI) is an imaging tech­
nique which is used to visualize the internal structure 
and function of  the body. MRI provides excellent tissue 
contrast, which is much greater than that of  any other 
imaging modality[1,2]. Tissue contrast is realized by a wide 
range of  pulse sequences. For example, tissue contrast 
on T1­ and T2­weighted images is based on the rate at 
which signals from protons in water molecules in a static 
magnetic field decay following excitation by a sequence 
of  radiofrequency (RF) pulses. Diffusion weighted 
imaging (DWI) is another mechanism for developing 
image contrast and relies on changes in the diffusion 
properties of  water molecules in tissues. DWI is a widely 
accepted technique in neuroradiology for detecting early 
ischemia in cerebrovascular accidents and characterization 
of  brain tumors and intracranial infections[1­3]. The use 
of  DWI in other parts of  the body is relatively new, but 
very promising for the detection and differentiation of  
benign and malignant lesions, imaging for dissemination 
(i.e. staging) in oncological patients before treatment and 
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for follow­up after treatment of  liver tumors. Besides this, 
DWI is thought to be capable of  predicting the response 
to therapy of  malignant tumors (especially chemothe­
rapy)[4].
BASIC PRINCIPLES OF DWI
Diffusion
Diffusion is a physical property, which describes the 
microscopic random movement of  (water) molecules 
driven by their internal thermal energy. This movement 
is known as Brownian motion. In biological tissues, water 
diffusion is movement of  water molecules in intracellular, 
extracellular and intravascular spaces. Diffusion is affected 
by the biophysical properties of  tissue cell organization 
(cell membranes, fibers and macromolecules), density, 
microstructure and microcirculation. Intracellular water 
diffusion is more hindered than that in the extracellular 
spaces which are lacking natural barriers. Pathological 
processes which change the volume ratio or physical 
nature of  intra­ and extracellular spaces affect the diffusion 
of  water molecules. Restricted or impeded diffusion is 
seen in tissues with high cellularity, e.g. tumors, abscesses, 
fibrosis and cytotoxic edema. Relative free or unimpeded 
diffusion is encountered in tissues with low cellularity or 
tissues with disrupted cell membranes, for example in cysts 
and necrotic tissues[3­5] (Figure 1A and B). 
DWI
DWI relies on measuring diffusion of  water molecules in 
the tissue by MRI. It uses a pulse sequence (T2­weighted 
spin echo sequence) and 2 strong motion probing gra­
dients on either side of  the 180º refocusing pulse, known 
as the Stejskal­Tanner sequence. The first gradient, 
prior to the 180º RF pulse is the dephasing (diffusion 
sensitizing) gradient. The second gradient, after the RF 
pulse, is the rephasing gradient. In tissues with restricted 
diffusion, the effect of  the dephasing gradient is cancelled 
out by the rephasing gradient. This causes little impact 
on the overall T2 decay, reflected as a maintained T2 
signal in the tissue. When diffusion is not impeded, water 
molecules can move a considerable distance between the 
dephasing and rephasing gradients. The mobile water 
molecules will not be fully rephased and a reduction in 
overall T2 signal intensity follows.
DWI is sensitive to very small scale motion of  water 
molecules at a microscopic level. The sensitivity of  a 
DWI sequence is characterized by its b­value, expressed 
in s/mm2. The b­value summarizes the influence of  
the gradients in DWI. The higher the b­value, the more 
sensitive the sequence is to diffusion effects. DWI is 
performed with at least two b­values. Diffusion is quanti­
tatively reflected in a diffusion coefficient. The diffusion 
coefficient is related to the molecular mobility of  water 
molecules and reflects tissue properties such as the 
size of  the extracellular space, viscosity and cellularity. 
Diffusion coefficients in DWI are reflected in the apparent 
diffusion coefficient (ADC, expressed in mm2/s), apparent 
because it is a mean value of  diffusion contributed by 
movement of  intracellular, extracellular and vascular 
water molecules within an image voxel (volumetric pixel) 
at different b­values. Analysis of  ADC is an automated 
process, available as an application on most scanners or 
workstations. Calculation of  ADC is made for each voxel 
of  an image and can be displayed as a parametric (ADC) 
map. ADC measurements are then recorded for a given 
region by drawing regions of  interest (ROIs) on the ADC 
map. Low ADC values mean restricted diffusion, thus in 
tissues which are highly cellular. High ADC values are seen 
in areas with relative free diffusion, thus in tissues with low 
cellularity[1,3­5].
Problems encountered in DWI
DWI can be performed with different techniques, inclu­
ding spin­echo (SE), fast spin echo (FSE), gradient echo 
(GE) and echo­planar imaging (EPI). EPI is the gold 
standard DWI technique. When DWI is performed in 
the body, scanning can be carried out with free breathing, 
breath hold or respiratory triggered. There are some 
important limitations of  DWI[2,6].
Firstly, the signal­to­noise ratio (SNR, describes the 
relative contributions of  the true signal and background 
noise to a detected signal) and spatial resolution are 
low due to hardware limitations and high bandwidth (a 
measure of  frequency range, the range between the highest 
and lowest frequency allowed in the signal), inherent to 
the technique and EPI sequence. SNR will be decreased 
in incomplete spin echo formation, as is the case with 
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Figure 1  Brownian movements in hypocellular (A) and hypercellular (B) 
environment. A: Tissue with low cellularity permits movement of the water 
molecules; B: Tissue with high cellularity restricts the movement of water 
molecules.
the most common DWI technique, the EPI sequence. 
SNR can be increased, but then spatial resolution is 
sacrificed[2,3,6­8].
Secondly, DWI is susceptible to a number of  artifacts. 
Ghosting images and blurring may arise from motion, 
caused by respiratory, cardiac and voluntary movements. 
Tissue contrast is maintained during free­breathing 
scanning, but breath hold and respiratory triggered tech­
niques reduce image blurring. Breath hold scans have 
very short acquisition times of  20­30 s (i.e. the time the 
patient holds his or her breath) and are theoretically less 
likely to be degraded by motion­related artifacts. A disad­
vantage of  breath­hold scanning is that the patient needs 
to hold his or her breath for a considerable time, which 
may be difficult when the physical condition does not 
allow him or her to do so. Respiratory triggering will 
make the acquisition time of  the images longer (5 min), 
especially when the patient is breathing irregularly or 
slowly, but this is a minimal time penalty. Respiratory 
triggering provides substantially improved signal, spatial 
resolution and the ADC values are comparable to breath­
hold DWI. In respiratory triggering, multiple b­values can 
be used to reduce errors in ADC calculation[2,3,6,7,9­11]. 
Motion artifacts caused by the heart beating alter 
ADC in the left lobe of  the liver, making measurements 
unreliable. Cardiac motion can be overcome by using electr­
ocardiographic­triggering, but cardiac gating is not always 
reliable and increases acquisition times significantly[2,3,6,7,12].
Susceptibility artifacts are due to magnetic field inho­
mogeneity (to be overcome by shimming techniques) 
or metal artifacts and are seen as bright spots, spatial 
distortion or signal drop out. Susceptibility artifacts occur 
especially in fast imaging techniques like EPI[2,6,7]. 
Artifacts caused by air­tissue interfaces or fat­water 
interfaces (chemical shift) appear as black or bright bands 
at the edge of  an anatomical structure. Other artifacts 
are eddy currents, resulting from the rapid on and off 
switching of  the gradients, leading to geometrical distortion 
and image shearing artifacts[2,6,7].
Pathological diffusion
When evaluating diffusion on DWI images, the radiologist 
focuses on the measurement of  extracellular diffusion. 
As mentioned earlier, the higher the cellularity in a tissue, 
the less far is extracellular water able to diffuse during 
the MR observation period without being blocked by cell 
membranes. Highly cellular tissues provide a short path of  
diffusion, resulting in low ADC values, as is seen in solid 
liver lesions and abscesses. Low cellularity means that 
there are fewer structural barriers, making the diffusion 
path longer. This results in high ADC values as is seen 
in cysts and necrotic lesions. In summary, ADC maps, 
derived from DWI provide a non­invasive measure of  
cellularity. This makes DWI a potential tool in diagnosis, 
treatment planning and monitoring, especially in onco­
logy[3­5]. Examples of  different types of  lesions and their 
diffusion weighted images are seen in Figures 2­5.
DWI IN THE LIVER
There are an increasing number of  studies dealing with 
quantitative measurements of  ADC in liver lesions, but 
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Figure 2  Magnetic resonance imaging (MRI) and diffusion weighted imaging (DWI) of a cyst. A: T1-weighted MRI; B: T2-weighted MRI; C: Diffusion weighted 
image (b-value 50 s/mm2); D: Diffusion weighted image (b-value 1000 s/mm2) in a 33-year old woman with multiple liver lesions. The cyst is hypo-intense on the 
T1-weighted image, hyper-intense on the T2-weighted image and the diffusion weighted image at a b-value 50 s/mm2. Note that the cyst totally disappears on the 
diffusion weighted image at a b-value 1000 s/mm2.
A B
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Figure 3  MRI and DWI of an adenoma and a hemangioma. A: T1-weighted MRI; B: T2-weighted MRI; C: Diffusion weighted image (b-value 50 s/mm2); D: Diffusion 
weighted image (b-value 1000 s/mm2) in a 41-year-old women with multiple liver lesions. The large lesion in segment 8 is an adenoma and the small one in segment 2-3 
is a hemangioma. On the T1-weighted image, the adenoma is slightly hypo-intense to the normal liver parenchyma, and hyper-intense on the T2-weighted image. On 
the diffusion weighted images, it remains hyper-intense at both b-values. The hemangioma is also hypo-intense on the T1-weighted image and hyper-intense on the 
T2-weighted image. However, in contrast to the adenoma, it totally disappears at a b-value of 1000 mm/s2.
A B
C D
Figure 4  MRI and DWI of hepatocellular carcinoma. A: T1-weighted; B: DWI (b-value 50 s/mm2); C: Diffusion weighted image (b-value 1000 s/mm2) in a 67-year-
old male with hemophilia, hepatitis C-based liver cirrhosis and HCC in segment 7. The HCC is hypo-intense on the T1-weighted image and hyper-intense on the 
diffusion weighted images at both b-values. Note that the lesion remains hyper-intense on the image with a b-value 1000 s/mm2.
A B
C D
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there are as many discrepancies in the reported ADC 
values (Table 1). This is often associated with the choice 
of  b­values and other technical parameters. Low b­values 
lead to overestimation of  the ADC due to the contribution 
of  perfusion to the diffusion measurement. Large b­values 
underestimate ADC due to increasing contributions from 
low ADC components and SNR.
DWI as a tool for characterization of liver lesions
Several studies have suggested that the measurement of  
ADC values is useful in the characterization of  focal liver 
lesions[13­26]. Reduced ADC values have been reported for 
most malignant tumors. This finding is thought to be the 
result of  cellular membranes impeding the mobility of  
water molecules. However, solid benign lesions, which 
are also highly cellular, exhibit decreased ADC values as 
well. Abscesses do so too because their viscose content 
with bacteria, inflammatory cells, mucoid proteins and cell 
debris result in restricted diffusion, thus low ADC values. 
On the other hand, necrotic and cystic malignancies 
show high ADC values resulting from larger diffusion 
distances as a consequence of  lost membrane integrity. 
Benign lesions as simple cysts and hemangiomas show 
high ADC values because of  their liquid content and 
large extracellular spaces. However, ADC values cannot 
discriminate between solid benign and malignant lesions, 
since there is considerable overlap. According to Feuerlein 
et al[15], the pretest probability of  malignancy is very 
important in the determination to which degree a large 
ADC value is predictive for a malignancy, i.e. the history, 
demography and clinical picture of  the individual patient. 
Even ADC values of  lesions of  the same kind show 
overlap and there is no cut­off  value for ADC values 
in normal parenchyma, benign and malignant lesions. 
In the literature, ADC values vary between 0.94­2.85 × 
10­3 mm2/s for metastases and 0.69­2.28 × 10­3 mm2/s 
for normal liver parenchyma. This is mainly because 
every study group uses their own scanning parameters. 
Differences in b­values are the main cause of  non­
equivocal results. Breath­hold, respiratory triggered and 
navigator echo techniques can also give different ADC 
values. There is need for an uniformly applicable scanning 
protocol to eliminate discrepancies in ADC values caused 
by different scanning parameters[13].
DWI alone is not suitable for the characterization of  
liver lesions, because solid benign lesions also can show 
restricted diffusion, and cystic or necrotic malignant 
lesions have unimpeded diffusion. DWI can help direct 
the attention of  the radiologist to findings that may 
otherwise be overlooked. Unenhanced and dynamic MRI 
contrast series alone are very capable in the discrimination 
of  different types of  liver lesions, but a combination of  
DWI and MRI increases the accuracy of  the characteri­
zation of  benign and malignant lesions[15­17].
Detection of hepatocellular carcinoma
Multiphase multidetector contrast enhanced computed 
tomography (CT) has reached a high standard for the 
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Figure 5  MRI and DWI of hepatic metastases. A: T1-weighted; B: T2-weighted; C: Diffusion weighted image (b-value 50 s/mm2); D: Diffusion weighted image (b-value 
1000 s/mm2) in a 74-year-old woman with a history of rectal cancer, recently diagnosed with lung and liver metastases in segment 4 and 8, respectively. The lesions are 
hypo-intense to the liver parenchyma on the T1-weighted image and hyper-intense on the T2-weighted image. On the diffusion weighted image at a b-value 50 s/mm2, 
both lesions appear hyper-intense, but at a b-value 1000 s/mm2, only the lesion in segment 4 remains hyper-intense. The lesion in segment 8 has completely disappeared.
A B
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evaluation of  the cirrhotic liver and for the detection 
of  hepatocellular carcinoma (HCC). On CT images, 
diagnosis of  HCC is made based on neovascularization 
with increased arterial enhancement and rapid portal 
venous wash­out. In the last few years, (liver­specific) 
contrast enhanced multiphase dynamic MRI has increa­
singly been used for the detection of  HCC. MRI proved 
to be superior to CT in the detection of  HCC and for 
the characterization of  nodules in patients with liver 
cirrhosis because of  the high tissue contrast provided 
by MRI and the available liver­specific contrast agents. 
Contrast enhanced MRI is now regarded as the best non 
invasive imaging modality. However, even with liver­
specific contrast enhanced MRI, there is a diagnostic 
problem for small HCC lesions (< 10 mm) as well as in 
the differentiation from other non­malignant nodules. 
Large HCC lesions are well­recognized on conventional 
MRI by their rapid enhancement in the arterial phase and 
their contrast agent wash­out in the portal­venous phase. 
Small HCC is less typical on conventional MRI, and 
differentiation of  atypical nodules in the cirrhotic liver is 
challenging[27­31].
Xu et al[27,28] found that ADC values were not useful 
in cirrhotic livers, because cirrhotic parenchyma and 
solid benign lesions have low ADC values. They cannot 
be differentiated from lesions with malignant diffusion 
restriction because of  the considerable overlap among 
their ADC values. Necrosis and vascularization within 
HCC also alter diffusion, often seen as a false increase in 
the ADC values.
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Table 1  Reported ADC values in different types of lesions in the liver
Study Type of lesion n ADC value mm2/s, BH (SD) ADC value mm2/s, RT (SD)
Taouli et al[10]
b-values Benign 18 2.21 (0.60) 2.39 (0.44)
0, 50, 500 s/mm2 Malignant 11 1.04 (0.27) 1.16 (0.33)
Goshima et al[13]
b-values Hemangioma 12 1.23-2.23 (0.2-1.2)2
100, 200, 400, 800 s/mm2 Cyst 15 3.70-4.72 (0.9-1.2)2
Metastases 7 0.99-1.70 (0.5-1.1)2
HCC 21 1.08-1.79 (0.3-10.9)2
Kandpal et al[14]
b-value Hemangioma 11 2.22 (0.45) 2.36 (0.48)
0, 500 s/mm2 Cyst 11 2.66 (0.44) 2.90 (0.51)
FNH 3 2.03 (0.24) 2.15 (0.18)
Abscess 6 1.21 (0.36) 1.13 (0.43)
Metastases 38 1.06 (0.36) 1.13 (0.41)
HCC 12 1.22 (0.34) 1.27 (0.42)
Gourtsoyianni et al[18]1
b-values Hemangioma 7 1.90
0, 50, 500, 1000 s/mm2 Cyst 15 2.55
Metastases 13 0.99 (0.22)
HCC 2 1.38
Oner et al[19]
b-values Hemangioma 5 1.72 (0.30)
0, 500 s/mm2 Cyst 3 2.34 (0.36)
Metastases 6 1.03 (0.24)
Demir et al[23]1
0, 1000 s/mm2 Benign 24 1.09-3.36 (0.32/0.28)3
Malignant 17 0.54-1.24 (0.07/0.14)3
Bruegel et al[24]1
b-values Hemangioma 56 1.92 (0.34)
50, 300, 600 s/mm2 Cyst 51 3.02 (0.31)
FNH 4 1.40 (0.15)
Metastases 82 1.22 (0.31)
HCC 11 1.05 (0.09)
Holzapfel et al[25]1
b-values Hemangioma 18 1.69 (0.34)
50, 300, 600 s/mm2 Cyst 71 2.61 (0.57)
FNH/adenoma 6/9 1.43 (0.22)
Metastases 76 1.08 (0.32)
HCC 17 1.12 (0.28)
1These studies found significantly higher ADC values in benign liver lesions than in malignant liver lesions; 2This study evaluated the ADC values at different 
b-values. The lowest and highest ADC values are reported here. The lowest ADC value corresponds with the highest b-value, the highest ADC value with the 
lowest b-value; 3This study evaluated the ADC values of different types of benign and malignant lesions. The lowest and highest ADC values are reported 
here. ADC: Apparent diffusion coefficient; BH: Breath-hold; RT: Respiratory triggered; SD: Standard deviation; FNH: Focal nodular hyperplasia; HCC: 
Hepatocellular carcinoma.
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Zech et al[29] reported a higher sensitivity for DWI 
compared to conventional MRI in the detection of  HCC 
in the cirrhotic liver (98% for DWI vs 83%­85% for MRI). 
Vandecaveye et al[30] concluded that DWI provided higher 
sensitivity and positive predictive value for the detection 
of  HCC < 20 mm compared to conventional contrast 
enhanced MRI (sensitivity and specificity 91.2% and 82.9% 
vs 67.6% and 61.6%, positive predictive value 81.6% and 
59.0%, respectively). DWI did not show significantly better 
results than conventional MRI in detecting HCC > 20 mm. 
These findings can be explained by the better contrast­to­
noise ratio and background suppression of  normal liver 
parenchyma and vascular or bile structures in DWI, which 
make small lesions more visible, especially when they are 
in close vicinity to vessels or bile ducts. DWI provides a 
high negative predictive value on the presence or absence 
of  HCC and reduces the rate of  unnecessary invasive 
diagnostic procedures and follow­up. 
Detection of liver metastases
Several studies have demonstrated the usefulness of  
DWI in the detection of  liver metastases. They compared 
DWI to unenhanced and dynamic liver specific contrast 
enhanced MRI (Table 2).
 Coenegrachts et al[20] showed that lesion conspicuity 
of  hemangiomas and metastases is significantly higher 
with respiratory triggered DWI at low b­values compared 
to conventional unenhanced MRI imaging. This is due to 
an excellent lesion to liver contrast and suppression of  
background signals from vessels.
Koh et al[32] compared the diagnostic accuracy of  
DWI and mangafodipir trisodium (MnDPDP)­enhanced 
MRI alone and in combination in the detection of  colore­
ctal liver metastases. They found that a combination 
of  MnDPDP MRI and DWI resulted in the highest 
diagnostic accuracy (0.94­0.96 vs 0.88­0.92 for MnDPDP 
alone and 0.83­0.90 for DWI alone) with an increased 
sensitivity, but no loss of  specificity. DWI alone is not 
useful because the sequence is very susceptible to motion 
artifacts, which obscure lesions and make images difficult 
to interpret. This is especially the case in the left lobe 
of  the liver. They also stated that experience is needed 
to interpret DWI correctly, mainly because of  the large 
numbers of  artifacts on the images[33].
Parikh et al[34] reported a significantly higher overall 
lesion detection rate for breath­hold or respiratory trigg­
ered DWI than for conventional T2­weighted MRI (88% vs 
70%). Bruegel et al[35] compared respiratory DWI­EPI with 
T2­TSE. They found a sensitivity and specificity for T2­
TSE MRI of  45%­62% for unenhanced MRI and 88%­91% 
for DWI­EPI for lesions > 10 mm. When considering 
only small metastases < 10 mm, the differences between 
DWI and conventional MRI with and without contrast 
are even more pronounced: a sensitivity of  85% for DWI­
EPI and 26%­44% for T2­TSE. Lesion detection on T2­
TSE is hindered by low lesion to liver contrast and by 
the interfering bright signal from intrahepatic vessels. 
Lesion conspicuity with DWI is excellent and limitation 
of  the DWI sequence is predominantly referred to lesion 
characterization rather than to lesion detectability.
Nasu et al[36] assessed the diagnostic accuracy of  res­
piratory triggered DWI in combination with unenhanced 
MRI vs superparamagnetic iron oxide (SPIO)­enhanced 
imaging. On the basis of  a receiver operator characteristic 
analysis (ROC), averaged over 3 observers, they found a 
sensitivity and specificity for SPIO­enhanced images of  
66% and 90% and for DWI 82% and 94%, respectively. 
Predicting response to therapy of primary and 
secondary liver malignancies by DWI
Tumor responses to chemotherapy and radiation the­
rapy are conventionally assessed by measurement of  
percentage reduction in tumor size after chemotherapy. 
However, tumor size measurement on CT or MRI is 
insensitive to early treatment changes. Theoretically, DWI 
is sensitive to microenvironmental changes in tumors that 
occur after treatment. Studies on the predictive value of  
DWI in primary cancer demonstrated a strong negative 
correlation between mean pre­treatment ADC values and 
percentage size reduction of  tumors after chemotherapy 
and chemoradiation. High pretreatment ADC values in 
tumors were associated with a poor response to chemo­
therapy[37,38].
Koh et al[37] showed that high pre­treatment ADC 
values in colorectal liver metastases were predictive of  
a poor response to oxaliplatin and 5­fluorouracil­based 
chemotherapy. They determined with ROC that a mean 
pretreatment ADC150­500 (ADC map with b­values 
150 s/mm2 and 500 s/mm2) of  1.69 × 10­3 mm2/s had 
60% sensitivity and 100% specificity for identification 
of  non­responding metastatic lesions. They found also 
a significant linear regression relation between mean 
ADC150­500 and percentage in tumor size reduction 
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Table 2  Performance of DWI and conventional MRI in the 
detection of liver metastases  n  (%)
Study Sensitivity Specificity Accuracy PPV NPV
Vandecaveye et al[30]
> 20 mm
B600 SI ratio 100    81.8 94.9 93.3 100
T2-CE MRI      96.4    81.8 92.3 93.1      90.0
< 20 mm
B600SI ratio      91.2    82.9 86.7 81.6      91.9
T2-CE MRI      67.6    61.0 64.0 59.0      69.4
Koh et al[32]1
MnDPDP MRI      81.3    93.0 88-92
DWI 0, 150, 500 BH      78.3    95.0 83-90
MnDPDP MRI and DWI      92.2    97.0 94-96
DWI RT        88-91
T2 MRI        45-62
Nasu et al[36]
DWI RT (0, 500)  82 94
SPIO MRI  66 90
1In this study, 2 observers reviewed the images. The given values in 
sensitivity, specificity and diagnostic accuracy refer to the separate results 
of both observers. PPV: Positive predictive value; NPV: Negative predictive 
value.
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after treatment. Responding tumors showed a significant 
increase in ADC values at the end of  the treatment. Non­
responding tumors and liver parenchyma did not show 
significant changes in ADC values. Cui et al[38] analyzed 
87 liver metastases of  colorectal and gastric origin in 23 
patients. They also found significant lower ADC values 
in responding tumors than in non­responding ones. 
ADC increased in responding metastases, but not in 
non­responding ones. They found a weak correlation 
between tumor size reduction and pretreatment ADC 
values. The theoretical background for these findings is 
that higher ADC values are observed in necrotic tissue, 
and in tissue with loss of  cell membrane integrity. When 
these changes are present before chemotherapy, it may 
indicate a more aggressive phenotype. Necrotic regions 
within a tumor are usually poorly perfused, resulting in 
less delivery of  chemotherapeutic agents to these areas. 
Necrotic regions areas are also exposed to a more hypoxic 
and acidic environment, which diminishes the effect of  
chemotherapy. Necrosis in hepatic metastases is present 
in almost half  of  the cases. A possible explanation for 
non­responding tumors with lower ADC values may be 
the fact that necrosis is not always associated with high 
ADC values, especially in the case of  coagulation necrosis 
without cell lysis or liquefaction. The increase in ADC 
values at the end of  the treatment suggests a change from 
a more cellular pretreatment to a less cellular or necrotic 
phenotype.
Only one study assessed DWI in HCC treatment 
with sorafenib. Schraml et al[39] showed that ADC values 
with sorafenib, an angiogenesis inhibitor for treatment of  
HCC, actually showed a decrease instead of  an increase. 
This may be a result of  ischemia, induced by inhibition 
of  angiogenesis. The extracellular volume is decreasing, 
leading to lower ADC values during treatment. They also 
often observed hemorrhage within the tumors (55%), 
which may contribute to a decrease in ADC. However, 
progression of  HCC more than 3 mo after therapy was 
related to a decrease in ADC values. Only conventio­
nal MRI could differentiate between hemorrhage and 
tumor progression. Pre­treatment HCC had high ADC 
values, because of  rich vascularization of  the tumors. 
ADC changes early after chemotherapy seem to reflect 
the underlying mechanisms in tumor necrosis, most 
probably hemorrhagic, induced by the novel targeted 
agent sorafenib early after therapy and may indicate tumor 
reactivation in the later follow­up period.
DWI after locoregional treatment for liver tumors
Locoregional therapy for liver tumors is used in patients 
who are not eligible for surgery. The most commonly used 
local ablative therapies are radiofrequency ablation (RFA) 
and transcatheter arterial chemoembolization (TACE). 
The success of  these procedures is determined by the rate 
of  ablation site recurrences (ASR), i.e. tumor recurrence 
as result of  incomplete ablation. Close and careful follow­
up is needed in patients who underwent treatment by RFA 
and TACE to detect ASR at an early stage. Unfortunately, 
diagnostic management remains an issue in these patients, 
because of  difficulties in differentiating ASR from non­
tumoral tissue changes after thermal therapy. Since 
DWI can provide information about molecular tissue 
characteristics, it may have an additional value in the 
evaluation and follow­up of  local ablative therapies in 
patients with liver tumors.
There is one study which evaluated the time­related 
diffusion alterations after hepatic RFA with regard to 
potential diagnostic information for the detection of  
ASR. Schraml et al[40] reviewed 54 oncological patients 
treated by RFA for liver metastases from different origins. 
The ablation zone did not show significant alterations at 
different time points. Measurement of  the ADC value 
of  the entire ablation zone was not suitable for the 
detection of  ASR, because locally changing ADC values 
were masked by the heterogeneous appearance of  the 
entire ablation zone. Peripheral zones should be analyzed 
separately. An important technical limitation of  ADC 
measurements after RFA is that the limited spatial reso­
lution does not allow exact ROI positioning in the narrow 
peripheral rim. Viable tumors after RFA appeared as 
hyper­intense, and necrotic regions were recognized as 
hypointense areas on DWI. ASR showed significantly 
lower ADC values than the ablation zone and normal liver 
parenchyma (1.02 × 10­3 mm2/s vs 1.31 × 10­3 mm2/s). 
Suspected areas on DWI were more easily identified 
and analyzed in conjunction to conventional MR. Signal 
alterations in the periphery, especially ones with lower 
ADC values should raise suspicion on ASR. Edema, 
inflammation, fibrosis and necrosis are associated with 
higher ADC values. DWI together with conventional 
imaging is a promising tool in the evaluation of  the post­
RFA liver and may contribute to the detection of  ASR.
The use of  DWI after TACE in HCC has recently 
been investigated. Goshima et al[41] reported significant 
increases in ADC values after TACE, but they varied 
widely and did not contribute to the accurate diagnosis 
of  tumor necrosis by any cut­off  points. Yu et al[42] found 
that DWI added to conventional MRI could increase the 
sensitivity for determining ASR especially in the case of  
atypical lesions. However, they also noticed an increase 
in the number of  false positive findings by adding 
DWI which affected the overall accuracy of  MRI. This 
was caused by perilesional inflammation and arterial 
reperfusion of  the perilesional atrophic area after TACE. 
ADC measurement was not helpful for distinguishing 
viable tumors from perilesional nontumorous changes, 
since there was great overlap between the ADC values 
of  both entities.
CONCLUSION
DWI in the liver is a relative new and increasingly used 
imaging technique in addition to conventional unenhanced 
and contrast enhanced MRI. DWI proved to be helpful 
in the characterization of  focal liver lesions, but should 
always be used in conjunction with traditional MRI since 
there is great overlap between ADC values of  benign 
and malignant lesions. DWI is useful in the detection of  
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small HCC in the cirrhotic liver, with higher sensitivity, 
specificity and positive predictive value compared to 
conventional contrast enhanced imaging due to better 
lesion to liver contrast and background suppression of  
signals arising from vessels and bile ducts. This is also the 
case for the detection of  metastases in the liver. However, 
it should be noted that DWI images are difficult to 
interpret since DWI is very sensitive to artifacts. It seems 
reasonable to use DWI in conjunction to conventional 
imaging. DWI is not yet commonly used in the follow­
up after treatment of  liver malignancies. Pre­treatment 
ADC values in tumors treated with chemotherapy seem 
to be useful in the prediction and evaluation of  the 
treatment response of  primary and secondary liver malig­
nancies. DWI in the follow­up after RFA and TACE 
shows promising results in the detection of  ablation site 
recurrences, especially in combination with conventional 
contrast enhanced imaging.
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